What is a stock summary page? Click here for an overview.
Business Description
Q32 Bio Inc
NAICS : 541714
SIC : 2833
Description
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.13 | |||||
| Equity-to-Asset | 0.06 | |||||
| Debt-to-Equity | 3.33 | |||||
| Debt-to-EBITDA | -0.43 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -14.5 | |||||
| 3-Year EPS without NRI Growth Rate | -37.3 | |||||
| 3-Year FCF Growth Rate | -36.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.77 | |||||
| 9-Day RSI | 45.45 | |||||
| 14-Day RSI | 42.11 | |||||
| 3-1 Month Momentum % | -42.95 | |||||
| 6-1 Month Momentum % | -95.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.97 | |||||
| Quick Ratio | 4.97 | |||||
| Cash Ratio | 4.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.7 | |||||
| Shareholder Yield % | -56.82 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -45.86 | |||||
| ROIC % | -294.99 | |||||
| 3-Year ROIIC % | -167.98 | |||||
| ROC (Joel Greenblatt) % | -593.18 | |||||
| ROCE % | -52.88 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.51 | |||||
| Price-to-Tangible-Book | 3.5 | |||||
| EV-to-EBIT | 0.87 | |||||
| EV-to-EBITDA | 0.88 | |||||
| EV-to-FCF | 0.58 | |||||
| Earnings Yield (Greenblatt) % | 114.94 | |||||
| FCF Yield % | -340.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Q32 Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.615 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 42.11 | ||
| 14-Day ATR (€) | 0.201012 | ||
| 20-Day SMA (€) | 1.623 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 1.09 - 46.4 | ||
| Shares Outstanding (Mil) | 12.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Q32 Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Q32 Bio Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Q32 Bio Inc Frequently Asked Questions
What is Q32 Bio Inc(STU:DB0)'s stock price today?
The current price of STU:DB0 is €1.47. The 52 week high of STU:DB0 is €46.40 and 52 week low is €1.09.
When is next earnings date of Q32 Bio Inc(STU:DB0)?
The next earnings date of Q32 Bio Inc(STU:DB0) is 2025-05-30 Est..
Does Q32 Bio Inc(STU:DB0) pay dividends? If so, how much?
Q32 Bio Inc(STU:DB0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers